Yahoo Canada Web Search

Search results

  1. Daniel Louis Doctoroff (born July 11, 1958 [1]) is an American businessman and former government official. [2] From 2015 to 2021, he served as Chief Executive Officer of Sidewalk Labs, a startup company he helped found focused on technology for city life.

  2. Having lost both his father and uncle to ALS, Daniel L. Doctoroff founded Target ALS, a transformative biomedical research nonprofit, in 2013 to accelerate discovery of effective treatments for ALS. In October 2021, Dan himself was diagnosed with ALS.

    • daniel l. doctoroff - new orleans ds new orleans images today1
    • daniel l. doctoroff - new orleans ds new orleans images today2
    • daniel l. doctoroff - new orleans ds new orleans images today3
    • daniel l. doctoroff - new orleans ds new orleans images today4
    • daniel l. doctoroff - new orleans ds new orleans images today5
  3. www.targetals.org › community › founderFounder - Target ALS

    DANIEL L. DOCTOROFF. Having lost both his father and uncle to ALS, Daniel L. Doctoroff founded Target ALS in 2013 in collaboration with Bloomberg Philanthropies and financier and philanthropist David Rubenstein to create a new collaborative framework for scientists.

  4. Aug 2, 2023 · Doctoroff has now set a goal of raising $250 million for Target ALS, the research foundation he co-founded after his uncle’s diagnosis. “Nobody’s ever raised that much money for ALS...

  5. Mar 22, 2024 · Told through the eyes of the individuals who worked with Doctoroff to lead these projects and accompanied by more than 450 photos, The Urbanist: Dan Doctoroff and the Rise of New York tells...

  6. Daniel Doctoroff. Chairman and Founder, Target ALS. CONNECT. Daniel L. Doctoroff stepped down as Chairman and CEO of Sidewalk Labs, Alphabet’s pioneering urban innovation company, in late 2021 upon being diagnosed with ALS.

  7. People also ask

  8. Doctoroff and his team created a new collaborative model of research that has been a major catalyst to understanding the genetics and biology of ALS and has lowered the barriers to entry for new scientific discovery, and has helped to induce over 100 biotech, pharmaceutical, and venture capital firms to demonstrate interest in the disease.

  1. People also search for